Related Experiment Video
Updated: Oct 3, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Intravenous mirtazapine in the treatment of depressed inpatients
A Konstantinidis1, J Stastny, J Ptak-Butta
1Department of General Psychiatry, University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Abstract:
Mirtazapine is a novel antidepressant with a noradrenergic and specific serotonergic mode of action. So far, mirtazapine has been administered orally. This naturalistic study evaluates the antidepressant efficacy, safety, and tolerability of mirtazapine 15 mg/day administered intravenously to 27 inpatients with moderate to severe major depression. Compared with baseline, we found a significant decrease of the Hamilton Depressive Rating Scale (HDRS) total score (P<0.001). Side effects were mild and transient. Altogether, the results of this preliminary study show that intravenous mirtazapine is an effective, safe and well tolerated treatment for depressed inpatients.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Electroconvulsive Therapy
Mania and Antimanic Drugs: Overview
